BioLife Solutions vs Haemonetics
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put BioLife Solutions and Haemonetics side by side, using each one’s latest annual report. Here is what stands out:
- Haemonetics is the larger business, with $1.3B of revenue in fiscal 2026 against $96.2M for BioLife Solutions, about 14 times as much.
- BioLife Solutions grew revenue faster (28.9%, against −2.0%).
- Haemonetics kept more of each dollar of sales as operating profit (11.8% operating margin, against −17.3%).
- Haemonetics turned more of its sales into free cash flow (19.5% FCF margin, against 11.1%).
- Haemonetics earned a higher return on the capital invested in it (6.7%, against −4.8%).
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
BioLife Solutions
BLFS
3/10
Revenue growth5-year growthGross margin
Haemonetics
HAE
7/10
Operating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreShare count change
Side by side
Best in the row
| Latest fiscal year | BLFS FY25 | HAE FY26 |
|---|---|---|
| Size | ||
| Market cap | — | $5.4B |
| Revenue | $96.2M | $1.3B |
| Free cash flow | $10.6M | $260M |
| Net income | −$4.6M | $97.3M |
| Growth | ||
| Revenue growth | 28.9% | −2.0% |
| 5-year growth | 14.9% | 8.9% |
| Share count change | 5.6% | −6.7% |
| Profitability | ||
| Gross margin | 64.6% | 59.0% |
| Operating margin | −17.3% | 11.8% |
| Net margin | −4.8% | 7.3% |
| FCF margin | 11.1% | 19.5% |
| Return on capital | −4.8% | 6.7% |
| Return on equity | −1.3% | 12.0% |
| Balance sheet | ||
| Net debt | −$83.9M | $994M |
| Net debt / EBITDA | — | 3.7x |
| Dividends and buybacks | $0.0M | $175M |
| Valuation & quality | ||
| P/E | — | 57.3x |
| Piotroski F-score | 6 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.